Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
gkbpgdyjWvVbfR0m
